

ASX / MEDIA RELEASE



Compumedics Director share transaction notification

Melbourne, Thursday 5 April, 2007. Compumedics Limited (ASX code: CMP)
Compumedics today announced that D & DJ Burton Holdings Pty Ltd, the major shareholder in Compumedics and a company controlled by Mr. Burton, Executive Chairman of Compumedics, has sold 340,517 ordinary shares in Compumedics Limited, representing 0.003% of the issued shares of Compumedics.

The shares have been sold to improve liquidity in Compumedics shares as Mr. Burton is entitled to further equity in the Company as a result of the redeemable convertible notes (RCNs) on issue and held by D & DJ Burton Holdings Pty Ltd. The net result of the current transaction and payment of the first years interest due on the RCNs via the issue of shares will be to further increase the total number of securities held by D & DJ Burton Holdings Pty Ltd and other entities controlled by Mr. Burton from 64.2% to 64.7% of the total issued shares of the Company.

For further information:

David Burton
Executive Chairman, CEO
Phone: +61 3 8420 7300
Fax: +61 3 8420 7399

David Lawson
Company Secretary/CFO
Phone: +61 3 8420 7307
Fax: +61 3 8420 7399

About Compumedics

Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices.

In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, currently exceeding 12,000 studies with 20,000 patients scheduled by 2008. The company has corporate headquarters in Melbourne, Australia and offices in the United States, Asia and Europe.

In 1998 Compumedics was awarded the overall Australian Exporter of the Year.

In 2000 Compumedics was listed on the Australian Stock Exchange.

In 2002, Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan hold around 90% of the market for brain-research products. This acquisition has enabled Compumedics to take advantage of the synergies between research and clinical-based Neuro Diagnostic technologies, re-affirming our commitment as a world-class developer of both sleep and neuro-diagnostic systems.

In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy.

In 2004, Compumedics acquired German-based DWL Elektronische GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields.

Compumedics has grown to become a global medical diagnostic company with world leadership in three of the most exciting high-growth sectors and some 12,000 systems installed. Compumedics businesses now include their core and pioneering sleep-diagnostics (Sleep Division), Neuro-diagnostics (Neuroscan and Neuroscience Divisions), and non-invasive blood-flow diagnostics (DWL Division). All of these fields were pioneered or discovered in the 1980s, validated in the 1990s and are only now undergoing rapid commercialisation into the rapidly expanding \$1 billion plus global market.

The company has increased its sales more than 4 fold from \$9 million (1999) to \$38 million (2005), reflecting its continued commitment to an effective sales and R&D organisation.

www.compumedics.com